Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer
Preclinical results demonstrate pelareorep activity is maintained in the presence of RAS inhibition Findings support further evaluation of pelareorep’s potential to deepen and prolong responses to RAS-targeted therapy SAN DIEGO, Sept. 10, 2026 (GLOBE NEWSWIRE) — Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage immunotherapy company developing pelareorep, today announced positive preclinical […]
Financial Post
Published by CurrentWire · First coverage
Compiled by CurrentWire News Desk
Summary based on reporting from Financial Post.
Automated coverage analysis
Generated automatically from the coverage listed on this page. CurrentWire adds no editorial claims.
Coverage
1 publication is covering this story.
How CurrentWire compiled this story
Financial Post (financialpost.com), a Tier B publisher, filed this report on . CurrentWire published this page 13 minutes later, on .
Signal breakdown
CurrentWire ranked this story 55.3 of 100 in the snapshot this page was rendered from.
- Freshness
- 34.3 of 35
- Source authority
- 7 of 20
- Coverage breadth
- 4 of 20
- Geographic relevance
- 3.5 of 10
- Story prominence
- 6.5 of 10
- Velocity
- 0 of 5
Strongest signal: freshness, 34.3 of 35. How each signal is calculated.
Filed under Business · International · Press release. Topics extracted from this report, with other live CurrentWire stories mentioning each: Positive Preclinical Results Combining Pelareorep (none), Pan-RAS Inhibitor (none), Colorectal Cancer (none).
CurrentWire is a news discovery platform. This page summarizes and links to original reporting; full articles, imagery and copyright remain with the publishers listed above.